Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BWAY 
Brainsway Ltd (BWAY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: BWAY (3-star) is a STRONG-BUY. BUY since 29 days. Profits (33.40%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $15.05
Year Target Price $15.05
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 380.61% | Avg. Invested days 59 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 249.79M USD | Price to earnings Ratio 60.09 | 1Y Target Price 15.05 |
Price to earnings Ratio 60.09 | 1Y Target Price 15.05 | ||
Volume (30-day avg) - | Beta 0.25 | 52 Weeks Range 5.67 - 13.25 | Updated Date 06/29/2025 |
52 Weeks Range 5.67 - 13.25 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 9.01% | Operating Margin (TTM) 4.99% |
Management Effectiveness
Return on Assets (TTM) 1.42% | Return on Equity (TTM) 7.41% |
Valuation
Trailing PE 60.09 | Forward PE 81.97 | Enterprise Value 179529006 | Price to Sales(TTM) 5.75 |
Enterprise Value 179529006 | Price to Sales(TTM) 5.75 | ||
Enterprise Value to Revenue 4.13 | Enterprise Value to EBITDA 27.31 | Shares Outstanding 18894900 | Shares Floating 23596812 |
Shares Outstanding 18894900 | Shares Floating 23596812 | ||
Percent Insiders 6.4 | Percent Institutions 32.27 |
Analyst Ratings
Rating 4.75 | Target Price 15.05 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Brainsway Ltd
Company Overview
History and Background
Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel. It develops and markets non-invasive neurostimulation products based on Deep Transcranial Magnetic Stimulation (Deep TMS) technology. The company has focused on expanding its technology for the treatment of various neurological and psychiatric disorders.
Core Business Areas
- Deep TMS Systems: Design, development, and sales of Deep TMS systems for the treatment of various brain disorders. This includes the device itself and related accessories.
- Treatment Coils: Development and sale of specialized coils used with the Deep TMS systems, tailored for specific clinical applications.
- Services and Support: Providing training, maintenance, and support services to customers using Brainsway's Deep TMS systems.
Leadership and Structure
Hadar Levy serves as the Chief Executive Officer. The company operates with a board of directors and various departments focusing on research and development, sales, marketing, and operations. The company is structured around its core technologies and clinical applications.
Top Products and Market Share
Key Offerings
- Deep TMS System for Depression: Brainsway's flagship product, approved by the FDA for the treatment of major depressive disorder (MDD) in adults who have failed to respond to antidepressant medications. Market share data for specific depression TMS systems is difficult to obtain precisely, but Brainsway is a key player in the TMS market. Competitors include Neuronetics (STIM), MagVenture, and CloudTMS. Revenue from this product constitutes a significant portion of Brainsway's total revenue.
- Deep TMS System for OCD: FDA-cleared for the treatment of obsessive-compulsive disorder (OCD). Similar to MDD, Brainsway holds a significant share in the TMS treatment for OCD. Neuronetics (STIM), MagVenture, and CloudTMS are also competitors here.
- Deep TMS System for Smoking Cessation: FDA-cleared for short-term smoking cessation in adults. Limited market share data is available but the company sees this market as a growth opportunity. Competitors include Neuronetics (STIM) and MagVenture.
Market Dynamics
Industry Overview
The neuromodulation market, particularly Transcranial Magnetic Stimulation (TMS), is growing due to increasing awareness of mental health disorders and the demand for non-invasive treatment options. The industry is driven by technological advancements, clinical research, and regulatory approvals.
Positioning
Brainsway is positioned as a leader in Deep TMS technology, offering a broader stimulation range and potentially greater efficacy compared to traditional TMS. Its competitive advantage lies in its proprietary technology and clinical evidence supporting its effectiveness.
Total Addressable Market (TAM)
The global TMS market is estimated to reach billions of dollars in the coming years. Brainsway is positioned to capture a significant share of this market through continued innovation and expansion into new clinical applications.
Upturn SWOT Analysis
Strengths
- FDA-cleared Deep TMS technology
- Strong intellectual property portfolio
- Established presence in the neuromodulation market
- Positive clinical trial results demonstrating efficacy
Weaknesses
- High cost of Deep TMS systems
- Limited insurance coverage in some regions
- Competition from other neuromodulation technologies
- Relatively small company size compared to larger competitors
Opportunities
- Expansion into new clinical applications (e.g., Alzheimer's disease)
- Increasing awareness and acceptance of TMS therapy
- Strategic partnerships with hospitals and clinics
- Development of next-generation TMS technology
Threats
- Regulatory changes impacting TMS reimbursement
- Emergence of competing technologies
- Economic downturn affecting healthcare spending
- Negative publicity regarding TMS safety or efficacy
Competitors and Market Share
Key Competitors
- STIM
- MAGV
- None
Competitive Landscape
Brainsway's advantage lies in its Deep TMS technology. However, Neuronetics (STIM) has a larger established base. The competition is based on technology, clinical evidence, market reach, and reimbursement coverage.
Growth Trajectory and Initiatives
Historical Growth: Brainsway's historical growth has been driven by the adoption of its Deep TMS technology in the treatment of depression and OCD. Revenue growth rates would be analyzed over the past several years.
Future Projections: Future growth projections would be based on analyst estimates and the company's own guidance. Factors such as market penetration, expansion into new clinical applications, and regulatory approvals would influence these projections.
Recent Initiatives: Recent strategic initiatives could include partnerships with healthcare providers, expansion into new geographic markets, and investments in research and development.
Summary
Brainsway demonstrates moderate financial strength, showing potential in the neuromodulation sector. Its Deep TMS technology, though innovative, faces competition and reimbursement challenges. Continued expansion into new applications and strategic partnerships are crucial for sustainable growth, while monitoring regulatory and economic influences.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is based on estimates and may not be precise. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Brainsway Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1999-10-06 | CEO - | ||
Sector Healthcare | Industry Medical Devices | Full time employees 120 | Website https://www.brainsway.com |
Full time employees 120 | Website https://www.brainsway.com | ||
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.